Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.230 +0.060 (+2.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease ↗
David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
News headline image
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio's Earnings Outlook ↗
 
Via Benzinga
News headline image
INmune Bio Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Earnings Preview: INmune Bio ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023 ↗
 
Via Benzinga
BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer
Via Investor Brand Network
What to Know About the Future of Cancer Treatment
Via StatePoint Media
News headline image
INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines ↗
 
Via Benzinga
News headline image
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
The 7 Best Biotech Stocks for Personalized Medicine Investors ↗
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
News headline image
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Dow Jumps 250 Points; US Jobless Claims Increase Last Week ↗
U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday. The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose,... 
Via Benzinga
News headline image
Nasdaq Tumbles 150 Points; Crude Oil Up 1.5% ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 150 points on Wednesday. The Dow traded down 0.27% to 34,063.42 while the NASDAQ fell 1.33% to 11,952.51. The... 
Via Benzinga
News headline image
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
From INmune Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.